Skip to main
DOCS

Doximity (DOCS) Stock Forecast & Price Target

Doximity (DOCS) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 24%
Buy 24%
Hold 48%
Sell 5%
Strong Sell 0%

Bulls say

Doximity is a healthcare company with a positive outlook due to their increasing revenues and growing AI product usage, which will lead to a year of AI investment. Despite declining metrics, the company has reported record high engagement as doctors turn to their AI products, and they have also announced partnerships and product updates, positioning them for future growth. However, there are risks that could impede the stock, such as competition, M&A, and regulatory changes, as well as the potential for cybersecurity breaches or investments that could impact profitability.

Bears say

Doximity is facing challenges in the near-term due to market pressures, lower brand spend, and increased investments in AI. However, their adoption of AI could lead to positive outcomes in the second half of the fiscal year. While competition and potential budget limitations may impact their growth, VEEV is seen as a strong competitor in the healthcare industry.

Doximity (DOCS) has been analyzed by 21 analysts, with a consensus rating of Buy. 24% of analysts recommend a Strong Buy, 24% recommend Buy, 48% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Doximity and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Doximity (DOCS) Forecast

Analysts have given Doximity (DOCS) a Buy based on their latest research and market trends.

According to 21 analysts, Doximity (DOCS) has a Buy consensus rating as of Aug 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Doximity (DOCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.